BioNTech SEBNTXNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank53
5Y CAGR-39.9%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-39.9%/yr
Long-term compound
Percentile
P53
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 10.94% |
| Q2 2025 | -3.14% |
| Q1 2025 | -14.09% |
| Q4 2024 | 11.18% |
| Q3 2024 | -5.87% |
| Q2 2024 | 15.19% |
| Q1 2024 | -12.17% |
| Q4 2023 | 16.05% |
| Q3 2023 | 33.34% |
| Q2 2023 | 11.80% |
| Q1 2023 | -34.48% |
| Q4 2022 | 49.15% |
| Q3 2022 | -14.46% |
| Q2 2022 | 39.82% |
| Q1 2022 | 5.27% |
| Q4 2021 | 4.26% |
| Q3 2021 | 29.49% |
| Q2 2021 | -6.98% |
| Q1 2021 | -16.54% |
| Q4 2020 | 13.77% |
| Q3 2020 | 139.18% |
| Q2 2020 | 46.24% |
| Q1 2020 | -0.50% |
| Q4 2019 | 29.83% |
| Q3 2019 | -5.63% |
| Q2 2019 | -6.71% |
| Q1 2019 | 10.51% |
| Q4 2018 | 57.96% |
| Q3 2018 | 12.19% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |